Form 4: Adverum Biotechnologies Director Granted Stock Options in Routine Filing

Adverum Biotechnologies, Inc. Director Scott M. Whitcup was granted 10,450 stock options with an exercise price of $2.32, vesting on the earlier of June 17, 2026, or the 2026 annual meeting of stockholders.

Summary

• Scott M. Whitcup, a Director of Adverum Biotechnologies, Inc. (ADVM), was granted 10,450 stock options.
• The options have an exercise price of $2.32 per share.
• The transaction date for the grant was June 17, 2025.
• The options will vest and become exercisable on the earlier of June 17, 2026, or the 2026 annual meeting of stockholders.
• Vesting is subject to Mr. Whitcup's continued service with the Issuer on the vesting date.
• Accelerated vesting will occur upon a change of control.
• The options expire on June 16, 2035.

Sentiment

Score: 6

Explanation: Slightly positive as it represents a routine compensation event that aligns director interests with shareholders, without any negative surprises.

Positives

• The grant of stock options to a director aligns management's interests with those of shareholders, incentivizing long-term value creation.
• The vesting schedule encourages continued service and commitment from the director.

Negatives

• No specific negative information was disclosed in this routine Form 4 filing.

Risks

• The value of the stock options is subject to the future market price of Adverum Biotechnologies, Inc. common stock, which may fluctuate.
• Vesting is contingent on the reporting person's continued service, meaning the options could be forfeited if service ceases before vesting.
• Potential dilution for existing shareholders if the options are exercised in the future, although this is a standard aspect of equity compensation.

Future Outlook

The vesting schedule for the granted stock options indicates an expectation of continued service from Director Scott M. Whitcup until at least June 17, 2026, or the 2026 annual meeting of stockholders, aligning his incentives with the company's long-term performance.

Industry Context

The granting of stock options to directors is a common practice in the biotechnology and pharmaceutical industries, serving as a key component of executive and director compensation packages designed to attract and retain talent while aligning their financial interests with shareholder value creation. This practice is particularly prevalent in growth-oriented sectors like biotech, where long-term incentives are crucial.

Comparison to Industry Standards

• The use of stock options as a form of director compensation is a standard practice across the biotechnology sector, comparable to compensation structures at companies like Gilead Sciences, Amgen, or Biogen, which frequently utilize equity-based incentives.
• The vesting period, tied to continued service and accelerated upon a change of control, is also a common feature in such agreements, designed to retain key personnel and provide incentives during strategic transactions.
• The exercise price of $2.32, presumably the market price on the grant date, is typical for at-the-money option grants to ensure alignment with future stock performance.

Related Party Transactions

• The grant of stock options to Scott M. Whitcup, a Director of Adverum Biotechnologies, Inc., constitutes a related party transaction as it involves compensation provided by the company to a member of its board of directors.

Stakeholder Impact

• Shareholders: Potential for minor future dilution if options are exercised, but also improved alignment of director's interests with long-term shareholder value.
• Employees: No direct impact on general employees mentioned, but reflects standard executive compensation practices.

Next Steps

• The stock options will vest on the earlier of June 17, 2026, or the 2026 annual meeting of stockholders, subject to continued service.
• The options may be exercised by the reporting person at any time after vesting and before the expiration date of June 16, 2035.

Key Dates

Keywords

Adverum Biotechnologies, ADVM, Scott M Whitcup, Stock Options, SEC Form 4, Insider Transaction, Equity Compensation, Director Compensation, Biotechnology